You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理上調藥明生物(02269.HK)目標價至170.95元 評級「跑贏大市」
阿思達克 06-25 09:56
麥格理髮表研究報告指,藥明生物(02269.HK)受新冠病毒疫苗及抗體藥物複合體(ADC)項目帶動,預期未來將持續錄得強勁增長,將目標價上調40%至170.95元,相當於2023年預測市盈率80倍。

報告指,藥明生物管理層目標今年來自新冠相關項目的收入達到5億美元,明年並達到約3億至4億美元,但新冠相關積壓訂單已由10億增至12億美元,料將於未來兩年入帳,預期可支撐更高的市盈率。

該行又指,ADC市場未來五年年均複合增長率達48%,預期可成爲另一個增長動力,維持對藥明生物「跑贏大市」評級,將2021至2023年每股盈測上調5%至15%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account